JP2016501230A - 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体 - Google Patents

活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体 Download PDF

Info

Publication number
JP2016501230A
JP2016501230A JP2015545438A JP2015545438A JP2016501230A JP 2016501230 A JP2016501230 A JP 2016501230A JP 2015545438 A JP2015545438 A JP 2015545438A JP 2015545438 A JP2015545438 A JP 2015545438A JP 2016501230 A JP2016501230 A JP 2016501230A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
acid sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015545438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501230A5 (enExample
Inventor
ジャオ，シャオ−ヤン
ワン，ジュオジュイ
グゥ，ジャンミン
キム，ジ−ユン
バウゾン，マキシン
マーフィー，ジョン・イー
マクリーン，カーク
ジン，ファン
マルカルト，トビアス
ワン，シンチュエン
ビルメン，アンドレアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of JP2016501230A publication Critical patent/JP2016501230A/ja
Publication of JP2016501230A5 publication Critical patent/JP2016501230A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015545438A 2012-11-29 2013-11-27 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体 Pending JP2016501230A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261731294P 2012-11-29 2012-11-29
US61/731,294 2012-11-29
US201361786472P 2013-03-15 2013-03-15
US61/786,472 2013-03-15
PCT/US2013/072243 WO2014085596A1 (en) 2012-11-29 2013-11-27 MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)

Publications (2)

Publication Number Publication Date
JP2016501230A true JP2016501230A (ja) 2016-01-18
JP2016501230A5 JP2016501230A5 (enExample) 2017-01-12

Family

ID=50828462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545438A Pending JP2016501230A (ja) 2012-11-29 2013-11-27 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体

Country Status (18)

Country Link
US (1) US20150307625A1 (enExample)
EP (1) EP2925351A4 (enExample)
JP (1) JP2016501230A (enExample)
KR (1) KR20150088869A (enExample)
CN (1) CN104812402A (enExample)
AR (1) AR093671A1 (enExample)
AU (1) AU2013352159A1 (enExample)
BR (1) BR112015012414A2 (enExample)
CA (1) CA2892750A1 (enExample)
HK (1) HK1212896A1 (enExample)
IL (1) IL238658A0 (enExample)
MX (1) MX2015006424A (enExample)
RU (1) RU2015125349A (enExample)
SG (1) SG11201503719WA (enExample)
TW (1) TW201429992A (enExample)
UY (1) UY35154A (enExample)
WO (1) WO2014085596A1 (enExample)
ZA (1) ZA201504659B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
EP3831843A1 (en) * 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN116496394B (zh) * 2022-01-26 2024-07-23 东莞市朋志生物科技有限公司 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
US20250163183A1 (en) * 2022-03-04 2025-05-22 Coagulant Therapeutics Corporation Camelid antibodies against activated protein c and uses thereof
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
AU2024252640A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
JP2011500843A (ja) * 2007-10-26 2011-01-06 オクラホマ・メディカル・リサーチ・ファウンデーション 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
DE69735421T2 (de) * 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20030203355A1 (en) * 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
AU2005318171B2 (en) * 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
US7939637B2 (en) * 2005-12-13 2011-05-10 Medimmune Limited Insulin-like growth factor antibodies and uses thereof
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
JP2011500843A (ja) * 2007-10-26 2011-01-06 オクラホマ・メディカル・リサーチ・ファウンデーション 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. THROMBOSIS AND HAEMOSTASIS, 2002年, vol. 1, JPN6017032729, pages 662 - 670, ISSN: 0003628635 *
THE EMBO J., 1996年, vol. 15, no. 24, JPN6017032730, pages 6822 - 6831, ISSN: 0003628636 *

Also Published As

Publication number Publication date
AU2013352159A1 (en) 2015-06-04
AR093671A1 (es) 2015-06-17
KR20150088869A (ko) 2015-08-03
RU2015125349A (ru) 2017-01-10
CN104812402A (zh) 2015-07-29
ZA201504659B (en) 2017-11-29
EP2925351A1 (en) 2015-10-07
US20150307625A1 (en) 2015-10-29
BR112015012414A2 (pt) 2017-09-12
HK1212896A1 (zh) 2016-06-24
UY35154A (es) 2014-06-30
IL238658A0 (en) 2015-06-30
TW201429992A (zh) 2014-08-01
EP2925351A4 (en) 2016-08-24
MX2015006424A (es) 2015-08-14
WO2014085596A1 (en) 2014-06-05
CA2892750A1 (en) 2014-06-05
SG11201503719WA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
CA3081514C (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP6684369B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対する最適化されたモノクローナル抗体
JP2016501230A (ja) 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体
JP6559188B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6848016B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
JP2021091720A (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6419664B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
AU2013202752B2 (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK40017438A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK40017507A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP2018108089A (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
HK1226645A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1226645A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1156635B (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1156635A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1197829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180327